TheraCryf (LSE:TCF) ROCE % : -62.92% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TheraCryf's annualized ROCE % for the quarter that ended in Sep. 2023 was -62.92%.

TheraCryf ROCE % Historical Data

The historical data trend for TheraCryf's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf ROCE % Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-104.93

-100.19

-40.01

-30.34

-69.60

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial															-27.49	-34.03	-54.31	-91.30	-62.92

TheraCryf ROCE % Calculation

TheraCryf's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-5.07	/	( ( (9.638 - 0.411)	+	(6.174 - 0.833) )	/ 2 )
	=	-5.07	/	( (9.227	+	5.341)	/ 2 )
	=	-5.07	/	7.284
	=	-69.60 %

TheraCryf's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-2.918	/	( ( (6.174 - 0.833)	+	(4.35 - 0.415) )	/ 2 )
	=	-2.918	/	( ( 5.341	+	3.935 )	/ 2 )
	=	-2.918	/	4.638
	=	-62.92 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

TheraCryf (LSE:TCF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TheraCryf ROCE % Related Terms

Thank you for viewing the detailed overview of TheraCryf's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (LSE:TCF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

8EV:Germany

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.